[2]
Adiels M,Taskinen MR,Packard C,Caslake MJ,Soro-Paavonen A,Westerbacka J,Vehkavaara S,Häkkinen A,Olofsson SO,Yki-Järvinen H,Borén J, Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006 Apr;
[PubMed PMID: 16463046]
[3]
Johansen MØ,Nielsen SF,Afzal S,Vedel-Krogh S,Davey Smith G,Nordestgaard BG, Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study. Clinical chemistry. 2021 Jan 8;
[PubMed PMID: 33409531]
[4]
Balling M,Afzal S,Varbo A,Langsted A,Davey Smith G,Nordestgaard BG, VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. Journal of the American College of Cardiology. 2020 Dec 8;
[PubMed PMID: 33272366]
[5]
Dashti M,Kulik W,Hoek F,Veerman EC,Peppelenbosch MP,Rezaee F, A phospholipidomic analysis of all defined human plasma lipoproteins. Scientific reports. 2011;
[PubMed PMID: 22355656]
[6]
Dashty M,Motazacker MM,Levels J,de Vries M,Mahmoudi M,Peppelenbosch MP,Rezaee F, Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism. Thrombosis and haemostasis. 2014 Mar 3;
[PubMed PMID: 24500811]
[7]
Gibbons GF,Wiggins D,Brown AM,Hebbachi AM, Synthesis and function of hepatic very-low-density lipoprotein. Biochemical Society transactions. 2004 Feb;
[PubMed PMID: 14748713]
[8]
Tiwari S,Siddiqi SA, Intracellular trafficking and secretion of VLDL. Arteriosclerosis, thrombosis, and vascular biology. 2012 May;
[PubMed PMID: 22517366]
Level 2 (mid-level) evidence
[9]
Nimpf J,Schneider WJ, From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2. Biochimica et biophysica acta. 2000 Dec 15;
[PubMed PMID: 11111096]
[10]
Shelness GS,Sellers JA, Very-low-density lipoprotein assembly and secretion. Current opinion in lipidology. 2001 Apr;
[PubMed PMID: 11264986]
Level 3 (low-level) evidence
[11]
Teramoto R,Tada H,Kawashiri MA,Nohara A,Nakahashi T,Konno T,Inazu A,Mabuchi H,Yamagishi M,Hayashi K, Molecular and functional characterization of familial chylomicronemia syndrome. Atherosclerosis. 2018 Feb;
[PubMed PMID: 29153744]
[12]
Abifadel M,Boileau C, Genetic and molecular architecture of familial hypercholesterolemia. Journal of internal medicine. 2022 Oct 4;
[PubMed PMID: 36196022]
[13]
Sampson M, Wolska A, Meeusen JW, Donato LJ, Jaffe AS, Remaley AT. Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol. Frontiers in genetics. 2022:13():935257. doi: 10.3389/fgene.2022.935257. Epub 2022 Jul 14
[PubMed PMID: 35910208]
[14]
Rodrigues KF,Yong WTL,Bhuiyan MSA,Siddiquee S,Shah MD,Venmathi Maran BA, Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review. Biology. 2022 Sep 2;
[PubMed PMID: 36138787]
Level 3 (low-level) evidence
[15]
Grundy SM, Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. The American journal of cardiology. 1998 Feb 26;
[PubMed PMID: 9526809]
[16]
Wang J,Ban MR,Kennedy BA,Anand S,Yusuf S,Huff MW,Pollex RL,Hegele RA, APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nature clinical practice. Cardiovascular medicine. 2008 Nov;
[PubMed PMID: 18779834]
[17]
Fallat RW,Glueck CJ, Familial and acquired type V hyperlipoproteinemia. Atherosclerosis. 1976 Jan-Feb;
[PubMed PMID: 1078394]
[18]
Friedewald WT,Levy RI,Fredrickson DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972 Jun;
[PubMed PMID: 4337382]
[19]
Warnick GR,Knopp RH,Fitzpatrick V,Branson L, Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clinical chemistry. 1990 Jan;
[PubMed PMID: 2297909]
[20]
Martin SS,Blaha MJ,Elshazly MB,Brinton EA,Toth PP,McEvoy JW,Joshi PH,Kulkarni KR,Mize PD,Kwiterovich PO,Defilippis AP,Blumenthal RS,Jones SR, Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. Journal of the American College of Cardiology. 2013 Aug 20;
[PubMed PMID: 23524048]
[21]
Lambert JE,Parks EJ, Postprandial metabolism of meal triglyceride in humans. Biochimica et biophysica acta. 2012 May;
[PubMed PMID: 22281699]
[22]
Nakajima K,Nakano T,Tokita Y,Nagamine T,Inazu A,Kobayashi J,Mabuchi H,Stanhope KL,Havel PJ,Okazaki M,Ai M,Tanaka A, Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clinica chimica acta; international journal of clinical chemistry. 2011 Jul 15;
[PubMed PMID: 21531214]
[23]
Søndergaard E,Johansen RF,Jensen MD,Nielsen S, Postprandial VLDL-TG metabolism in type 2 diabetes. Metabolism: clinical and experimental. 2017 Oct;
[PubMed PMID: 28964326]
[24]
Lee HC,Shin SJ,Huang JK,Lin MY,Lin YH,Ke LY,Jiang HJ,Tsai WC,Chao MF,Lin YH, The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome. Lipids in health and disease. 2020 Sep 22;
[PubMed PMID: 32962696]
[25]
Gormsen LC,Høst C,Hjerrild BE,Gravholt CH,Nielsen S, Acute estrogen exposure does not affect basal very low-density lipoprotein-triglyceride production or oxidation in postmenopausal women. European journal of endocrinology. 2010 Sep;
[PubMed PMID: 20566588]
[26]
Sacks FM,Alaupovic P,Moye LA,Cole TG,Sussex B,Stampfer MJ,Pfeffer MA,Braunwald E, VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000 Oct 17;
[PubMed PMID: 11034934]
[27]
Gentile M,Iannuzzi A,Giallauria F,D'Andrea A,Venturini E,Pacileo M,Covetti G,Panico C,Mattiello A,Vitale G,Sarullo FM,Rubba P,Vigorito C,Panico S,Iannuzzo G, Association between Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Carotid Intima-Media Thickness in Postmenopausal Women Without Overt Cardiovascular Disease and on LDL-C Target Levels. Journal of clinical medicine. 2020 May 11;
[PubMed PMID: 32403373]
[28]
Ginsberg HN,Packard CJ,Chapman MJ,Borén J,Aguilar-Salinas CA,Averna M,Ference BA,Gaudet D,Hegele RA,Kersten S,Lewis GF,Lichtenstein AH,Moulin P,Nordestgaard BG,Remaley AT,Staels B,Stroes ESG,Taskinen MR,Tokgözoğlu LS,Tybjaerg-Hansen A,Stock JK,Catapano AL, Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal. 2021 Dec 14;
[PubMed PMID: 34472586]
Level 3 (low-level) evidence
[29]
Mendivil CO,Rimm EB,Furtado J,Sacks FM, Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. Journal of the American Heart Association. 2013 May 14;
[PubMed PMID: 23672999]
[30]
Marston NA,Giugliano RP,Melloni GEM,Park JG,Morrill V,Blazing MA,Ference B,Stein E,Stroes ES,Braunwald E,Ellinor PT,Lubitz SA,Ruff CT,Sabatine MS, Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA cardiology. 2022 Mar 1;
[PubMed PMID: 34773460]
[31]
Poulsen MK,Nellemann B,Stødkilde-Jørgensen H,Pedersen SB,Grønbæk H,Nielsen S, Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. The Journal of clinical endocrinology and metabolism. 2016 Apr;
[PubMed PMID: 26829441]
[32]
Tricò D,Natali A,Mari A,Ferrannini E,Santoro N,Caprio S, Triglyceride-rich very low-density lipoproteins (VLDL) are independently associated with insulin secretion in a multiethnic cohort of adolescents. Diabetes, obesity
[PubMed PMID: 30003666]
[33]
Giordano R,Picu A,Marinazzo E,D'Angelo V,Berardelli R,Karamouzis I,Forno D,Zinnà D,Maccario M,Ghigo E,Arvat E, Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clinical endocrinology. 2011 Sep;
[PubMed PMID: 21521323]
[34]
Baudrand R,Pojoga LH,Vaidya A,Garza AE,Vöhringer PA,Jeunemaitre X,Hopkins PN,Yao TM,Williams J,Adler GK,Williams GH, Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;
[PubMed PMID: 26432671]
[35]
Møller N,Jørgensen JO, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine reviews. 2009 Apr;
[PubMed PMID: 19240267]
[36]
Fabbrini E,Magkos F,Patterson BW,Mittendorfer B,Klein S, Subclinical hypothyroidism and hyperthyroidism have opposite effects on hepatic very-low-density lipoprotein-triglyceride kinetics. The Journal of clinical endocrinology and metabolism. 2012 Mar;
[PubMed PMID: 22238397]
[37]
Yogi-Morren D,Galioto R,Strandjord SE,Kennedy L,Manroa P,Kirwan JP,Kashyap S,Gunstad J, Duration of type 2 diabetes and very low density lipoprotein levels are associated with cognitive dysfunction in metabolic syndrome. Cardiovascular psychiatry and neurology. 2014;
[PubMed PMID: 25057411]
[38]
Miljkovic M,Stefanovic A,Simic-Ogrizovic S,Vekic J,Bogavac-Stanojevic N,Cerne D,Kocbek P,Marc J,Jelic-Ivanovic Z,Spasojevic-Kalimanovska V,Kotur-Stevuljevic J, Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease. Angiology. 2018 Nov;
[PubMed PMID: 29909653]
[39]
Butler LM,Perone Y,Dehairs J,Lupien LE,de Laat V,Talebi A,Loda M,Kinlaw WB,Swinnen JV, Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Advanced drug delivery reviews. 2020;
[PubMed PMID: 32711004]